The high wave will become a large player in the German medical center with the acquisition of shares in the Remexian Pharma GMBH
In the last 12 months, Remexian has income 65 million euros income
Remexian sold 7 tons of cannabis flower in the quarter of 2025, which is 43 tons of 16% imported to Germany in the quarter
Calgary, ABD, August 14, 2025 / PRNEWSWIRE / – High Tide Inc. (“High Termosity” or “Company”) (NASDAQ. HITI) (FSE: PHARMA GMBH (“Remexian”), 27.2 million euros (“transaction”) and will have an option to obtain the rest of interest in Remexia.
It was founded in 2018. Among the buyers of all Germany’s doctors, Remexian has one of the most popular in the world, which is currently licensed from 19 countries, including Canada, who represents about 33% of their total imports to Germany. Taking into account more than $ 1.9 billion from Canadian Canadian sales, a high channel has a Canadian shopping expertise and relationships to make this transaction significantly increase the Canadian Canadian department in Germany.
“Remexian is ideal for us, not only prices, but also with its operational approach, which prevents the highest price team. Said Raj Grover, the founder and CEO of the High Channel.
“With this high-quality acquisition, it’s about $ 100 million to significant EBITDA, we will talk about more affordable prices, which are imported to the highest quality brands,” Mr. Gurverer added.
“We are truly energy with a strong certigion that we have found with a high wave, the impressive scale of which enhances our influence in Germany,” said Remexyan co-founder Marcus Wenner. “Our two companies have deliberately have a strategic approach to becoming leaders in our relevant markets.
In April 2024, the demand for medical cannabis continued to accelerate in the country since the adoption of the German consumer Act of Germany. Over the past year, the number of medical cannabis has sharply increased by 250,000 to about 900,000 to 1 billion euros (BFAMM). 2025 (37.5 tons) and twelve months roll in total 134 tons, maintaining its place as the world’s largest medical importer. The growth of demand has also stimulated the position of Canada as a leading global exporter, the country’s German imports, about 36 tons in the first six months of 2025.
The Remexian, led by Francesco Baghan and Stefan Adome, is a leader in German Medical Cannabis, with an annual income, and 43 tons of 16 million euros and 15 million euros and a quarterly imported in Germany.
When the acquisition concluded, the company considered the potential of changes in Germany’s medical cannabis. The company believes that even if the restrictions are posted on telemedicine and postpone, which is subject to a long-term legislative review, the market will continue to grow after the adjustment period.
___________________________
Alcalculation agreements based on REMEX sales data and import numbers, which were publicly released by BFARM.
Oursource. War of flowers’ prices. German boom, the reality of Great Britain
³SOURCE: BFARM (Q2 2025 Update)
Alcalculation agreements based on REMEX sales data and import numbers, which were publicly released by BFARM.
Deal details
The transaction is subject to the wing length of time, among other things, it is necessary to exchange TSX enterprise (“TSXV”) and other customs conditions and are expected to be closed in the coming weeks. This implies a 53.4 million euros app that represents the 3,64065 times an annual Ebitda, which was created in six months of March 31, 2025, and is subject to certain adjustments based on working capital and closure. For 51% of the acquired equality, the preliminary estimated price of 27.2 million euros will be satisfied as follows:
42% of high-tidal tidal shares (“Ri-High Shares”) Price in US $ 2.1912, presenting the average average price for NASDAQ for NASDAQ.
29% cash.
29% of loans from sellers (“Credit”). The loan will ripen on December 31, 2029, annual annual interests (paid quarterly) will lead to a pre-payment company without penalty.
In addition to the above, the Remexian owners agreed to provide a high-channel option that acquires the remaining interests remaining in the Remexian through high tidal tide (“Call version”). The call option will be implemented at any time for a five (5) years of closing twenty four (24) monthly anniversary (“term” of the call version). The call option is carried out for the value of the enterprise, which is equal to the 12th Tebit Date of the Adjusted EBITDA, if the call version is performed in the first twelve (12) month of the call version. In addition, the high channel agreed to provide Remember owners to reset the remaining interests in high tidal lecture. Taking into account the option or set version, given the case, it will be satisfied with the Cash and High Combination Character at the discretion of the high wave. The call option has a minimum price of 15 million euros, and is subject to at least 40% of the payment of minimum cash, and the installed version is subject to at least 30% cash.
Any high levels related to the transaction are subject to four months and one day of stateration.
About a high wave
High Tide, Inc. is a leading community, retail Cannabis, developed to unleash the full cost of the world’s most powerful factory. The whole subsidiary of it, Canna Kabana, is the second largest brand of Cannabis in the world. High wave (HITI) is unique around cannabis consumer, fully diversified and fully integrated with all components of cannabis, including:
Bricks & Mortar Retail. Canna CABANA is Canada’s largest retail network in Canada, 203 Current places that pass through British Columbia, Alberta, Saskakateva, Manitoba, Ontario. In 2021, Kanina Cabana became the retail sale of the Cannabis Discount Club in the world.
Retail innovation. Fastendr ում is a unique and fully automated technology that uses retail kiosks to facilitate better purchase experience with observation, order and pickup.
Consumption accessories. The high wave operates the world’s leading e-commerce platforms, including grasscity.com, Smokecartel.com, DailyHighclub.com and Dankstop.com.
Brands. The list of HIGH Wave Industry and Consumer Brand includes Bud ™, Daily High Club Wea, Daily High Club ™, Vodka Glass Pass ™, Donezilla ™, Atomik ™ etc.
CBD. High channel continues to develop consumer CBD capabilities via Nuleafnaturals.com, fabcbd.de and brabscbd.co.uk.
Wholesale distribution. The high wave keeps the category of cannabis through wholesale solutions through Valiant.
Licensing. The high channel continues to push the culture of Cannabis through fresh partnership and license agreements under the name of the famous brandz.
The high tide is consistently moving forward before the fourth year in a row was named one of the best growing companies in Canada in 2024, as well as for the fastest growing companies in 1023. Tide, visit www.hightideinc.com. Do not miss high pages of high tidal tide in Sedan and Edgar for investment.
NCV NewsWire aims to treat high-quality content and information about cannabis companies by New Cannabis Ventures to help our readers make noise and remain the most important cannabical business news. NCV Newswire is hand treated by hand and is not automated. Have secret news tip. Contact:A number
You are reading this week’s edition of New Cannabis Ventures, a weekly magazine we have published since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve, as well as links to the most important news of the week. We no longer email them like we used to, but post this and all newsletters on our website here.
friends,
While the US is getting a lot of attention from cannabis investors, the industry faces many challenges in America. It’s been more than 12 years since Colorado shops opened their doors to adults beyond medical patients, and since then many states have embraced medical cannabis and adult cannabis. Although legal cannabis has expanded significantly, it remains a state-regulated market, and each state differs greatly in terms of rules and regulations. Cannabis remains illegal federally, and the industry continues to struggle 280E tax.
Cannabis markets outside the US continue to grow. Canada revised its federal medical cannabis program in 2013, with the MMPR replacing the MMAR, and the current Access to Cannabis for Public Purposes Regulations (ACMPR) replaced the MMPR in 2016. Justin Trudeau, who was elected Prime Minister in late 2015, became the first agenda item to legalize cannabis. implement adult use legalization in 2018. The program has its challenges, but the industry has grown as it has matured. StatsCan will release December sales data tomorrow, and it looks like cannabis sales are up about 4% for 2025.
Other countries have developed their own medical cannabis, including Australia, Germany and Israel, with Germany legalizing it for adult use. The Netherlands is holding trials in coffee shops. Uruguay, a small country, began legalizing cannabis sales to adults in 2017, and Germany began a program in 2024 to legalize cannabis for adults, although sales are through social clubs. While this program has not directly created commercial opportunities, it has boosted the market for medical cannabis. Unlike Canada, where cannabis is sold by the provinces, in Germany cannabis is sold in traditional pharmacies. A significant amount of medical cannabis sold in Germany is imported from Canada. David Brown of StratCann suggested this six months ago Almost 50% of German hemp imports in Q2 came from Canada.
The Global Hemp Stock Index, last recalculated at year-end, has 7 Canadian LPs, and these NASDAQ-listed companies tend to be active in international markets. Most MSOs in the US operate exclusively there, but one, Curaleaf, has international operations. Curaleaf trades on the TSX in Canada, but it trades in the US. The company reported total revenue of $320 million in its third quarter, with international operations (Canada, Germany, Portugal, Spain and the UK) accounting for just 14.4%. Year-to-date, it has registered just 12.9% as it has grown while domestic revenues have declined.
Canadian LPs in the index are Aurora Cannabis, Canopy Growth, Cronos Group, Organigram, SNDL, Tilray Brands and Village Farms. SNDL, which is more of an alcohol than cannabis retailer, has no international cannabis sales. The remaining six are active and active. This week, Organigram announced the acquisition of the rest of the German cannabis company, and it was already active in other markets. Cronos Group has announced the acquisition of CanAdelaar, a deal that is expected to close soon and will give it access to the Netherlands. Canopy Growth is acquiring MTL Cannabis, and increased exports of medical cannabis was a benefit he pointed to.
In: warned about Canadian LPs here at the end of November and I am now more optimistic about this part of the cannabis market. At the time I had 5 of the 7 GCSI members on my Focus List at 420 Investor, but I added Aurora Cannabis when they reported their financial Q3 and fell. Here’s how all 7 have performed since the end of November.
My 420 Investor model portfolio includes a small position in Tilray Brands, a large position in Aurora Cannabis, and a very large position in Organigram. These three positions represent 31.9% of the portfolio, while the GCSI has 27.4% exposure.
The Canadian LP market has certainly been cheaper than it is now, but it seems cheap enough. Balance sheets have improved dramatically, and some of these large companies are trading below tangible book value. NASDAQ listings are superior to the OTC listings that MSOs have. The Canadian market may improve, although I don’t expect it to, and international expansion may continue to help federally legal Canadian LPs export more or expand to other countries. These international operations also involve risks. I see a big international opportunity for Canadian LPs, and investors don’t seem very excited at the moment.
Sincerely,
Alan:
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is what we have published in the last 2 weeks.
Follow Alan for real-time updates X.com:. Share and discover industry news with like-minded people on the largest group of cannabis investors and entrepreneurs LinkedIn:.
Stay on top of the most important communications from public companies by watching what’s coming cannabis investor calendar.
Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El
Statistics Canada has released December retail sales for the country, with Cannabis sales are on the rise from November levels, up 5.3% to C$503.7 million, a new monthly record high. This sequential increase was up 1.9% on a daily basis due to more days than in the previous month. November, originally reported at C$477.9 million, was revised slightly higher to C$478.4 million. December sales rose 2.9% from a year earlier, up from 8.3% in May, 7.5% in June and 6.2% in September. This was also below the 20.3% growth rate in August 2023 and better than the previous lowest annual growth since the start of legalization, which started at -0.9% in September 2024 and then -1.6% in October due to the BC strike, and it was down significantly from the 9.1% growth in December 2024. The previous record level in August was only 1.8% above the previous year’s level. Total sales are expected to increase by 4.5% to C$5.39 billion in 2024 and by 4.1% to C$5.62 billion in 2025.
An increase in the number of shops, as well as a fall in the prices of flowers that attract consumers from the illegal market, have boosted sales. In Ontario, the most populous province, sales rose 6.5% from November but fell 4% from a year earlier. Alberta was up 5.7% from November, but down 1% from last year. British Columbia was up 5.2% from November and 22% from a year ago, while Quebec was down 1.6% from November and 10% from a year ago.
January sales data will be released on March 20.
Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El
This data-driven, fact-based search engine will be continually updated based on new financial filings so readers can stay up-to-date. Companies must file with the SEC or SEDAR and be current to be considered for inclusion. When we launched this resource in May 2019, companies with more than $2.5 million in quarterly revenue qualified. As the industry has grown and as more companies have gone public, we have raised the minimum several times, including $5 million in October 2019, $7.5 million in June 2020, up to $10 million in November 2020, $12.5 million in August 2021, $12.5 million in August 2021, and $202 in September 2021. million dollars. hemp industry, we raised the minimum again in May 2024. The senior list has a minimum of US$50 million (C$68.3 million) and the junior list now has a minimum of US$25 million (C$34.2 million).
Note on adjusted operating income
In May 2019, we added an additional measure, Adjusted Operating Income, which we detailed in our newsletter. The calculation takes reported operating income and adjusts it for any changes in the fair value of biological assets required under IFRS accounting. We believe this adjustment improves comparability between companies under IFRS and GAAP accounting. We note that operating income can often include one-time items such as stock compensation, inventory write-offs or public listing costs, and we encourage readers to understand how these non-cash items may impact quarterly financials. Many companies have moved from IFRS to US GAAP accounting, which has reduced our need to make adjustments. Please note that our rating only includes actual reported income and non pro forma income. We also note that companies with non-hemp operations must provide segment-level financial statements detailing not only revenue but also operating profit in order for their operating profit to be included in the tracking. Currently, Aurora Cannabis (NASDAQ: ACB ) (TSX: ACB ), Jazz Pharma (NASDAQ: JAZZ ) and Tilray (TSX: TLRY ) (NASDAQ: TLRY ) do not provide this information.
Tracker inclusion updates
At the time of our last update on October 21st, 19 companies were eligible for inclusion on the senior lists, including 14 in USD and 5 in Canadian currency, while there were 12 companies on the junior lists. Now, 15 companies denominated in US dollars and 4 denominated in Canadian dollars qualify for the senior lists, for a total of 19 now. The junior list includes 9 companies denominated in US dollars and 2 in Canadian dollars. Tracking public cannabis company revenue and earnings on a combined basis now includes 30 companies. American Junior List lost Scotts Miracle-Gro exits, including Hawthorne Gardening, when it reported its fiscal quarter due to its expected divestment. In Canada, Organigram (NASDAQ: OGI ) (TSX: OGI ) moved from the Senior List to the Junior List.
Companies that have reported since mid-November are included
Many of these companies are in December year-end and year-end reporting for them will begin very soon. There are several companies that have reported since the third quarter reports were released in November.
Senior and Junior – US Dollar Report
Neither company has yet reported Q3, but a flurry of updates begins next week. Tilray brands (NASDAQ: TLRY ) (TSX: TLRY ) reported its fiscal third quarter in early January. The diversified company grew its cannabis business 3% year over year as it grew 5% sequentially.
Several of the Big 5 MSOs have scheduled calls for their Q4 financial reports, although GTI has changed its policy and will not host any for now. Here is the current outlook of all of them.
Curaleaf (OTC: CURLF ) (TSX: CURA ) – revenue is expected to decline 1% year-over-year to $328.3 million, with adjusted EBITDA of $66.9 million, a 12% decline.
Green Thumb Industries (OTC: GTBIF ) (CSE: GTII ) – revenue is expected to increase 1% year over year to $296.1 million and adjusted EBITDA is expected to decline 20% to $78.6 million.
Trulieve (OTC: TCNNF ) (CSE: TRUL ) – Revenue is expected to decline 1% year-over-year to $296.5 million and adjusted EBITDA is expected to decline 8% to $95.9 million.
Verano Holdings (OTC: VRNO ) (NEO: VRNO ) – revenue is expected to decline 6% to $205.9 million and adjusted EBITDA is expected to decline 10% to $56.7 million.
Cresco Labs (OTC: CRLBF ) (CSE: CL ) – Revenue is expected to decline 9% to $160.9 million and adjusted EBITDA is expected to decline 12% to $36.3 million.
Senior and Junior – Canadian Dollar Report
Since the November 3rd quarter reports, High Tide (NASDAQ: HITI ) (TSXV: HITI ), Aurora Cannabis (NASDAQ: ACB ) (TSX: ACB ), Canopy Growth (NASDAQ: CGC ) (TSX: WEED ) and Organigram Global (NASDAQ: OGITS ) have filed to list (NASDAQ: OGITS ). Revenue grew sequentially for each of them except Organigram.
One of Canada’s senior listed members, SNDL, has yet to schedule its quarterly call.
The Public Cannabis Company Earnings Tracker by New Cannabis Ventures is not a recommendation of any company, and you should not use it as investment advice. A tilde next to a date means an approximate date. All calculations are derived from SEC or SEDAR filings. Any questions or licensing inquiries please contact us.
Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El
